id
related bits
0
processing priority
4
site type
3 (personal blog or private political site, e.g. Blogspot, Substack, also small blogs on own domains)
review version
11
html import
20 (imported)
first seen date
2024-11-10 08:12:26
expired found date
-
created at
2024-11-10 08:12:26
updated at
2025-10-21 17:50:53
length
23
crc
39811
tld
2211
nm parts
0
nm random digits
0
nm rare letters
0
is subdomain of id
69893241 (blogspot.com)
previous id
0
replaced with id
0
related id
-
dns primary id
0
dns alternative id
0
lifecycle status
0 (unclassified, or currently active)
deleted subdomains
0
page imported products
0
page imported random
0
page imported parking
0
count skipped due to recent timeouts on the same server IP
0
count content received but rejected due to 11-799
0
count dns errors
0
count cert errors
0
count timeouts
0
count http 429
0
count http 404
0
count http 403
0
count http 5xx
0
next operation date
-
server bits
—
server ip
-
mp import status
20
mp rejected date
-
mp saved date
-
mp size orig
235919
mp size raw text
1633
mp inner links count
51
mp inner links status
10 (links queued, awaiting import)
title
MS TOOLKIT...Updates in Research and Treatment...
description
A resource for informing patients and caregivers about Multiple Sclerosis, its possible causes, effects, and treatments. Get the most current information on new developments, clinical trials and other
image
site name
author
updated
2026-03-06 14:42:42
raw text
MS TOOLKIT...Updates in Research and Treatment... MS TOOLKIT...Updates in Research and Treatment... A resource for informing patients and caregivers about Multiple Sclerosis, its possible causes, effects, and treatments. Get the most current information on new developments, clinical trials and other important matters for anyone dealing with MS. Monday, January 26, 2009 Merck KGaA: Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Phase III Pivotal Trial • Two-year primary efficacy endpoint of CLARITY trial met: 58% relative reduction in annualized relapse rate in the low total dose treatment group and 55% in the high total dose treatment group • Submission for registration of cladribine tablets planned for mid-2009 • Cladribine tablets are the first oral investigational multiple sclerosis treatment to complete a two-year pivotal study Darmstadt, Germany, January 23, 2009 – Merck KGaA and its Merck Serono division...
redirect type
0 (-)
block type
0 (no issues)
detected language
1 (English)
category id
Pozostałe (16)
index version
1
spam phrases
0
text nonlatin
0
text cyrillic
0
text characters
1339
text words
232
text unique words
115
text lines
21
text sentences
7
text paragraphs
4
text words per sentence
33
text matched phrases
0
text matched dictionaries
0
links self subdomains
0
links other subdomains
links other domains
15 - merck.de, novartis.com, peptimmune.com, aegisthera.com, apitope.com, medpagetoday.com, sciencedaily.com, imt.ie, medicalnewstoday.com, avigen.com, genomeweb.com, prweb.com
links spam adult
0
links spam random
0
links spam expired
0
links ext activities
0
links ext ecommerce
0
links ext finance
0
links ext crypto
0
links ext booking
0
links ext news
1
links ext leaks
0
links ext ugc
152 - blogger.com
links ext klim
0
links ext generic
0
dol status
0
dol updated
2026-03-06 14:42:42
rss status
32 (unknown)
rss found date
2024-11-10 08:12:27
rss size orig
268017
rss items
25
rss spam phrases
1
rss detected language
1 (English)
inbefore feed id
-
inbefore status
0 (new)
sitemap path
sitemap status
40 (completed successful import of reports.txt file to table in_pages)
sitemap review version
2
sitemap urls count
699
sitemap urls adult
0
sitemap filtered products
0
sitemap filtered videos
0
sitemap found date
2024-11-10 08:12:26
sitemap process date
2025-01-12 08:05:42
sitemap first import date
-
sitemap last import date
2025-10-21 17:50:53